Foscarnet Sodium Hexahydrate

Foscarnet Sodium Hexahydrate

* Please be kindly noted products are not for therapeutic use. We do not sell to patients.

Foscarnet Sodium Hexahydrate
Category Antiviral
Catalog number BBF-05850
CAS 34156-56-4
Molecular Weight 300.04
Molecular Formula CH12Na3O11P
Purity 95%

Online Inquiry

Description

Foscarnet Sodium Hexahydrate is an antiviral drug used in the treatment of cytomegalovirus retinitis. It has inhibitory effect on viral DNA polymerase and reverse transcriptase.

Specification

Related CAS 4428-95-9 (anhydrous free acid) 63585-09-1 (anhydrous)
Synonyms Sodium phosphonoformate tribasic hexahydrate; 1,1-Dihydroxyphosphinecarboxylic Acid 1-Oxide Sodium Salt Hydrate; A 29622 Hydrate; EHB 776 Hydrate; Foscavir Hydrate; Gefin Hydrate; PFA Hydrate; Phosphonoformic Acid Trisodium Salt Hydrate; Triapten Hexahydrate; Trisodium Phosphonoformate Hexahydrate
Storage Store at 2-8°C
IUPAC Name trisodium;phosphonatoformate;hexahydrate
Canonical SMILES C(=O)([O-])P(=O)([O-])[O-].O.O.O.O.O.O.[Na+].[Na+].[Na+]
InChI InChI=1S/CH3O5P.3Na.6H2O/c2-1(3)7(4,5)6;;;;;;;;;/h(H,2,3)(H2,4,5,6);;;;6*1H2/q;3*+1;;;;;;/p-3
InChI Key ILRVASBWNRYBFD-UHFFFAOYSA-K

Properties

Appearance White to Off-white Solid
Antibiotic Activity Spectrum Viruses
Boiling Point 490.7 ℃
Melting Point >300°C
Solubility Soluble in Water (Sparingly, Heated)
LogP -1.00200

Reference Reading

1. Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial
Deepali Kumar, Barbara D Alexander, Diana F Florescu, Johan Maertens, Martha Fournier, Francisco M Marty, Catherine Cordonnier, Jingyang Wu, Sophie Alain, SOLSTICE Trial Investigators, Roy F Chemaly, Rafael F Duarte, Oliver Witzke, Emily A Blumberg, Nassim Kamar, Robin K Avery, Genovefa A Papanicolaou, Aimee K Sundberg, Fernanda P Silveira Clin Infect Dis . 2022 Sep 10;75(4):690-701. doi: 10.1093/cid/ciab988.
Background:Therapies for refractory cytomegalovirus infections (with or without resistance [R/R]) in transplant recipients are limited by toxicities. Maribavir has multimodal anti-cytomegalovirus activity through the inhibition of UL97 protein kinase.Methods:In this phase 3, open-label study, hematopoietic-cell and solid-organ transplant recipients with R/R cytomegalovirus were randomized 2:1 to maribavir 400 mg twice daily or investigator-assigned therapy (IAT; valganciclovir/ganciclovir, foscarnet, or cidofovir) for 8 weeks, with 12 weeks of follow-up. The primary endpoint was confirmed cytomegalovirus clearance at end of week 8. The key secondary endpoint was achievement of cytomegalovirus clearance and symptom control at end of week 8, maintained through week 16.Results:352 patients were randomized (235 maribavir; 117 IAT). Significantly more patients in the maribavir versus IAT group achieved the primary endpoint (55.7% vs 23.9%; adjusted difference [95% confidence interval (CI)]: 32.8% [22.80-42.74]; P < .001) and key secondary endpoint (18.7% vs 10.3%; adjusted difference [95% CI]: 9.5% [2.02-16.88]; P = .01). Rates of treatment-emergent adverse events (TEAEs) were similar between groups (maribavir, 97.4%; IAT, 91.4%). Maribavir was associated with less acute kidney injury versus foscarnet (8.5% vs 21.3%) and neutropenia versus valganciclovir/ganciclovir (9.4% vs 33.9%). Fewer patients discontinued treatment due to TEAEs with maribavir (13.2%) than IAT (31.9%). One patient per group had fatal treatment-related TEAEs.Conclusions:Maribavir was superior to IAT for cytomegalovirus viremia clearance and viremia clearance plus symptom control maintained post-therapy in transplant recipients with R/R cytomegalovirus. Maribavir had fewer treatment discontinuations due to TEAEs than IAT. Clinical Trials Registration.NCT02931539(SOLSTICE).
2. CMV retinitis treatment
J J Thimons Optom Vis Sci . 1995 May;72(5):310-1. doi: 10.1097/00006324-199505000-00007.
The two drugs known to be useful in the treatment of cytomegalovirus (CMV) retinitis are ganciclovir and foscarnet--usually they are given intravenously. Intravitreal ganciclovir seems to be even more effective. A pump system to deliver the drug into the vitreous is being developed.
3. Increased survival of a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis who received sodium phosphonoformate (foscarnet)
A G Palestine, J Falloon, H Masur, M D deSmet, M A Polis, J A Kovacs, R B Nussenblatt, R T Davey Jr, B F Baird, S Mellow Am J Med . 1993 Feb;94(2):175-80. doi: 10.1016/0002-9343(93)90180-w.
Purpose:To evaluate the impact of foscarnet on the longevity of persons with human immunodeficiency virus, type 1 (HIV-1) infection and cytomegalovirus (CMV) retinitis.Patients and methods:A cohort of 24 patients with acquired immunodeficiency syndrome (AIDS) and CMV retinitis received sodium phosphonoformate (foscarnet) as part of a controlled efficacy trial at the National Institutes of Health. Foscarnet was continued for as long as it was tolerated. Antiretroviral therapy was given to the patients as tolerated. Long-term follow-up was available on all patients.Results:Seventeen patients received zidovudine during or after receiving foscarnet, 2 patients received dideoxyinosine, 2 patients zidovudine and dideoxyinosine, and 3 patients received no specific antiretroviral agent. Patients received foscarnet for a mean of 6.2 months (median, 4 months; range, 10 days to 22 months). Ten patients required a change to ganciclovir therapy at some time after receiving foscarnet. The median time from the diagnosis of CMV retinitis until death was 13.5 months (range, 3 to 34 months). Patients lived longer than untreated or ganciclovir-treated historical controls with AIDS and CMV retinitis. There was no difference in the survival of patients treated with foscarnet at the time of diagnosis and those patients treated with foscarnet only after progression of their CMV retinitis.Conclusions:These data suggest that foscarnet may prolong the survival of persons with AIDS and CMV retinitis and should be the initial treatment of choice in these patients.

Bio Calculators

Stock concentration: *
Desired final volume: *
Desired concentration: *

L

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2

* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O c22h30n40
g/mol
g

Recently viewed products

Online Inquiry

Verification code
cartIcon
Inquiry Basket